On Wednesday, in the course of current trade, Shares of JetBlue Airways Corporation (NASDAQ:JBLU), dropped -5.52%, and is now trading at $20.55.
JetBlue Airways Corporation, declared plans for two new routes that will grow its presence in the Baltimore-Washington and Philadelphia metropolitan areas and continue its expansion in its focus cities in Orlando and Fort Lauderdale-Hollywood.
Starting November 12, JetBlue will operate new once daily service between Baltimore-Washington International Thurgood Marshall Airport (BWI) and Orlando International Airport (MCO) — the same day JetBlue launches formerly declared service between Baltimore and Fort Lauderdale-Hollywood. Within the National Capital Region, JetBlue also operates flights out of Ronald Reagan Washington National Airport (DCA) and Washington Dulles International Airport (IAD).
Starting November 19, JetBlue will operate twice daily service between Philadelphia (PHL) and Fort Lauderdale-Hollywood (FLL). Philadelphia is one of the largest markets JetBlue presently does not serve from Fort Lauderdale-Hollywood and will play a part in its growth towards 100 daily flights to meet increasing customer demand in South Florida.
JetBlue is offering an introductory fare of only $49 one way (a) from Baltimore-Washington to Orlando and from Philadelphia to Fort Lauderdale-Hollywood accessible on May 19, 2015. All introductory fare tickets must be purchased before May 20, 2015.
JetBlue Airways Corporation, a passenger carrier company, provides air transportation services. As of December 31, 2014, the company operated a fleet of 13 Airbus A321 aircrafts, 130 Airbus A320 aircrafts, and 60 EMBRAER 190 aircrafts.
During an Afternoon trade, Shares of Abbott Laboratories (NYSE:ABT), dipped -0.06%, and is now trading at $48.98, hitting its highest level.
Abbott Laboratories, declared that it has received CE Mark for the latest advancement of its Absorb stent system, called Absorb GT1™, which combines the world’s first fully dissolving stent with a next-generation delivery catheter to assist doctors treat people with heart disease. Built upon three generations of delivery catheter innovations, Absorb GT1 refers to the GlideTrack catheter, Abbott’s most advanced stent delivery system, which is designed to make it easier for doctors to access and treat diseased vessels in people with coronary artery disease (CAD). The GlideTrack catheter incorporates several design and technology changes that have the potential to improve deliverability and performance.
Last year, Abbott declared positive one-year clinical results from ABSORB II, the world’s first prospective, randomized, controlled trial comparing the safety and effectiveness of the fully dissolving Absorb heart device to Abbott’s market-leading, metallic XIENCE family of drug eluting stents. At one year, overall clinical outcomes for Absorb were comparable to XIENCE. The trial, conducted primarily in Europe, comprised of 501 people with CAD. At EuroPCR, a scientific meeting for cardiologists held in Paris, Absorb data will be presented throughout the conference, which runs from May 19-21, 2015. EuroPCR is the official congress of the European Association of Percutaneous Cardiovascular Interventions, with the aim of reducing the burden of cardiovascular disease.
Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome; intrahepatic cholestasis or depressive symptoms; gynecological disorders; dyslipidemia; hypertension; hypothyroidism; pain, fever, and inflammation; hormone replacement therapy; anti-infective and influenza vaccines; and product that regulates physiological rhythm of the colon.
Shares of The Goldman Sachs Group, Inc. (NYSE:GS), during its Wednesday’s current trading session fell -0.27%, and is now trading at $204.85.
The Goldman Sachs Group, plans to declare its 2015 Second Quarter Financial Results on Thursday, July 16th in a release that will be issued at about 7:30 am (ET).
A conference call to talk about the firm’s results, outlook and related matters will be held at 9:30 am (ET). The call will be open to the public.
The Goldman Sachs Group, Inc. operates as an investment banking, securities, and investment administration company worldwide. The company operates through four segments: Investment Banking, Institutional Client Services, Investing & Lending, and Investment Administration.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
